Reports
Reports
Chronic lymphocytic leukemia is a common type of leukemia diagnosed in adults. It is characterized by development of lymphocytes, also known as white blood cells, in the bone marrow, which travel through the blood. The lymphocytic leukemia cells are primarily found in the lymph nodes and other tissues. There are two types of chronic lymphocytic leukemia. One grows slowly, while the other is fatal. Generally, chronic lymphocytic leukemia does not cause any symptoms for a long time. Symptoms generally observed are swollen lymph nodes, fatigue, and easy bruising. Chemotherapy is the preferred treatment for chronic lymphocytic leukemia. Stem-cell transplant is used in rare cases. According to an article published by Apollo Hospitals, an estimated one million cases of chronic lymphocytic leukemia are diagnosed in India every year. Cancer statistics states that 1 in every 155 men and 1 in every 260 women in England are affected with chronic lymphocytic leukemia.
Rise in Prevalence of Lymphoma and Myeloma Cancer
Multiple myeloma is the third most common form of hematological malignancy after non-Hodgkin’s lymphoma and leukemia, and is characterized by uncontrolled proliferation of a clone of plasma cells within the bone marrow. According to the Leukemia & Lymphoma Society (LLS), around 176,200 people in the U.S. are expected to be diagnosed with leukemia, lymphoma, or myeloma in 2019. New cases of leukemia, lymphoma, and myeloma are anticipated to account for 10% of the estimated 1,762,450 new cancer cases diagnosed in the U.S. in 2019. Prevalence is the approximate number of people alive on a certain date in a population who previously had a diagnosis of the disease. An estimated 1,399,180 people in the U.S. are either living with, or are in remission from, leukemia, lymphoma, or myeloma.
Increase in Focus on Personalized Medicine
The concepts of personalized medicine have been subtly appreciated in medicine since the 1960s, with its first mention in a monograph title in 1998 and subsequent publication on the Medline interface in 1999. Advancement in genetic technologies, primarily single nucleotide polymorphism (SNP) genotyping and microarray/biochips, has been the pillar and driver of personalized medicine.
North America dominated the global market in 2020, followed by Europe. According to the World Health Organization, cancer is the leading cause of death across the world. According to the National Cancer Institute, about 1,735,350 new cases of cancer were diagnosed in the U.S. in 2018 and around 609,640 patients succumbed to the disease. Asia Pacific presents significant opportunities in the market. Investment in research & development for new drugs and expansion of pharmaceutical and biotechnology companies in India, China, and Japan are the key factors fueling the growth of the market in the region. Rise in disposable income in countries in Latin America such as Mexico and Brazil is expected to boost the growth of the chronic lymphocytic leukemia market in the region. Developing health care infrastructure in countries in the Middle East is projected to accelerate the growth of the chronic lymphocytic leukemia market in the region. Moreover, increase in government investment in health care and rise in presence of key players in Africa are anticipated to boost the market in Middle East & Africa.
The global chronic lymphocytic leukemia market is highly consolidated owing to the presence of small number of key players. Leading players operating in the global chronic lymphocytic leukemia market are:
Global Chronic Lymphocytic Leukemia Market, by Type of Cancer
Global Chronic Lymphocytic Leukemia Market, by Therapy
Global Chronic Lymphocytic Leukemia Market, by Route of Administration
Global Chronic Lymphocytic Leukemia Market, by End-user
Global Chronic Lymphocytic Leukemia Market, by Region
N/A
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Chronic Lymphocytic Leukemia Market
